ESPE Abstracts

Background: We recently described that 27.8% of patients treated with recombinant human GH (r-hGH) using the easypod had an adherence (AD) rate of <85.7% i.e. missing one r-GH dose per week. Overall AD of all investigated patients during the first 2 years of treatment was generally high (mean 90.2%).Objective: To evaluate the importance of high AD rate of r-GH administration over the first 2 years of r-hGH treatment on growth velocity and increase of...

Background: Mean adherence (AD) rates in patients treated with recombinant human GH (r-hGH) using either the easypod™ or a non-electronic (NEL) device have recently been reported.Objective and hypotheses: To evaluate AD rates of r-hGH treatment under everyday conditions and to calculate the amount of r-hGH administered using the easypod™ or a NEL device.Method: Retrospective, observational, open-label, non-controlled stud...

Background: Bioavailability of peptide/protein – drugs is extremely low after oral administration due to their instability in the gastrointestinal tract or poor absorption.Objective and hypotheses: Oral delivery of growth hormone and somatostatin by adding extreme stable lipids.Method: A liposomal system based on a combination of standard lipids and membrane spanning tetraether lipids, which are extremely stable biomolecules. ...